Ignite Creation Date:
2025-12-24 @ 3:21 PM
Ignite Modification Date:
2026-01-01 @ 12:22 PM
Study NCT ID:
NCT01655992
Status:
TERMINATED
Last Update Posted:
2018-01-23
First Post:
2012-07-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
Sponsor:
Fudan University
Organization:
Study Overview
Official Title:
A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.
Status:
TERMINATED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The sponsor decided to stop the study.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparing S1 generic With Capecitabine in Patients With Metastatic Breast Cancer.
Detailed Description:
Comparing S1 generic(Tegafur，Gimeracil and Oteracil Potassium Capsules) With Capecitabine in Patients With Metastatic Breast Cancer.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: